alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
================================================================================

Exhibit 31.1

Section 302 Certification of Chief Executive Officer and Chief Financial Officer

I, Daniel Brailey, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of ComLink
Communications Company.

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

   a) designed such disclosure controls and procedures to ensure that material
   information relating to the registrant, including its consolidated
   subsidiaries, is made known to us by others within those entities,
   particularly during the period in which this quarterly report is being
   prepared;

   b) evaluated the effectiveness of the registrant's disclosure controls and
   procedures as of a date within 90 days prior to the filing date of this
   quarterly report (the "Evaluation Date"); and

   c) presented in this quarterly report our conclusions about the effectiveness
   of the disclosure controls and procedures based on our evaluation as of the
   Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

   a) all significant deficiencies in the design or operation of internal
   controls which could adversely affect the registrant's ability to record,
   process, summarize and report financial data and have identified for the
   registrant's auditors any material weaknesses in internal controls; and

   b) any fraud, whether or not material, that involves management or other
   employees who have a significant role in the registrant's internal controls.

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant efficiencies and material weaknesses.


Date: November 13, 2006


/s/ Daniel Brailey
---------------------------
Daniel Brailey
Chief Executive Officer and
Chief Financial Officer


--------------------------------------------------------------------------------
Griselda GUTIERREZ, Employee, Plaintiff v. GDX AUTOMOTIVE, Employer, St. Paul Fire & Marine Insurance Company, Carrier, Defendants.

No. 240P05.

Supreme Court of North Carolina.

August 18, 2005.

Thomas M. Brooke, for Griselda Gutierrez.

*409Henry C. Byrum, Jr., Charlotte, for GDX & Insurance Co.

*ORDER*

Upon consideration of the petition filed on the 9th day of May 2005 by Plaintiff in this matter for discretionary review of the decision of the North Carolina Court of Appeals pursuant to G.S. 7A-31, the following order was entered and is hereby certified to the North Carolina Court of Appeals:

"Denied by order of the Court in conference, this the 18th day of August 2005."
CERTIFICATION PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


         In connection with the Quarterly  Report on Form 10-QSB for the quarter
ended April 30, 2006 (the  "Report") of SE Financial  Corp.  (the  "Company") as
filed with the Securities and Exchange  Commission on the date hereof, I, Pamela
M. Cyr, President,  Chief Executive Officer (Principal Executive and Financial &
Accounting Officer),  hereby certify,  pursuant to 18 U.S.C. ss.1350, as adopted
pursuant to ss.906 of the Sarbanes-Oxley Act of 2002, that:

(1)  The Report fully  complies  with the  requirements  of Section 13(a) of the
     Securities Exchange Act of 1934; and

(2)  The information  contained in the Report fairly  presents,  in all material
     respects, the financial condition and results of operations of the Company.



Date: June 14, 2006     /s/Pamela M. Cyr
                        --------------------------------------------------------
                        Pamela M. Cyr
                        President & CEO
                        (Principal Executive and Financial & Accounting Officer)
BROWN v. NORTH CAROLINA INDUS. COM'N

No. COA04-120.

Court of Appeals of North Carolina.

Filed March 1, 2005.

Certification Date March 21, 2005.

Case reported without published opinion. Affirmed.
Exhibit 32.1









CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of Scientific Energy, Inc. (the "Company") on Form 10-QSB for the period ending March 31, 2008, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Stanley Chan, President, CEO & CFO of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



(1)   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



(2)   The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.







|                                   | 
|---------------------------------- | 
|/s/ Stanley Chan                   | 
|Stanley Chan, President, CEO & CFO | 
|                                   | 



Dated: May 20, 2008
Exhibit 32.1





CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO TITLE 18,


UNITED STATES CODE, SECTION 1350, AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





I, James C. Clemmer, President, Chief Executive Officer and Director of ANGIODYNAMICS, Inc. (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to the best of my knowledge:


1.the quarterly report on Form 10-Q/A of the Company for the fiscal quarter ended August 31, 2016 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.





Date: July 25, 2017





/ s / James C. ClemmerJames C. Clemmer, President,Chief Executive Officer
#### Florence Okvist, Formerly Known as Florence Contro, Respondent, v Anthony Contro, Appellant.

[802 NYS2d 571]

Appeal from an order of the Supreme Court, Erie County (Christopher J. Burns, J.), entered April 7, 2004. The order, inter alia, denied defendant’s motion to reject the report of the Matrimonial Referee.

It is hereby ordered that the order so appealed from be and the same hereby is unanimously affirmed without costs.

Memorandum: Defendant appeals from an order that, inter alia, denied his motion pursuant to CPLR 4403 to reject the report of the Matrimonial Referee. We note at the outset that, although defendant appeals from the order in its entirety, he contends only that Supreme Court erred in denying that part of his motion with respect to his continuing obligation to pay maintenance to plaintiff, and he raises no issues on appeal concerning the propriety of that part of the order granting plaintiff s cross motion for, inter alia, maintenance arrears. Thus, defendant has abandoned his appeal with respect to those parts of the order concerning the remainder of his motion and concerning plaintiffs cross motion *(see Ciesinski v Town of Aurora,*202 AD2d 984 [1994]).

Defendant contends that his obligation to pay maintenance to plaintiff should be terminated pursuant to Domestic Relations Law § 248 because plaintiff is cohabiting with a man and “holds herself out as his wife, although [she is] not married to such man” *(id.).*The Matrimonial Referee found that, despite evidence that plaintiff resides with a man, that they attend family *1329functions and “various activities of their respective children together[,] and are generally considered a couple by those witnesses [who] testified” at the hearing, there is no evidence that plaintiff holds herself out as his wife. We conclude that the court properly confirmed the Matrimonial Referee’s report in that respect *(see generally*CPLR 4403). We note that the man with whom plaintiff resides testified that he and plaintiff share an apartment because of financial need and that, although they have a close friendship, they do not have a sexual relationship. Even assuming, arguendo, that the relationship between plaintiff and the man with whom she resides is of a romantic nature, we conclude that “[t]he record does not reveal any conduct by [plaintiff], either through direct action or by implication, indicating that she ever wished anyone to believe that she was married to [him,] nor does the evidence support such a belief’ *(Matter of Bliss v Bliss,*66 NY2d 382, 388 [1985]; *see Northrup v Northrup,*43 NY2d 566, 570-572 [1978]; *Szemansco v Szemansco,*11 AD3d 787 [2004]; *Charland v Charland,*267 AD2d 698, 699 [1999]; *Sitarek v Sitarek,*179 AD2d 1064, 1065 [1992]). Present—Scudder, J.P., Martoche, Smith, Pine and Hayes, JJ.
NOT FINAL UNTIL TIME EXPIRES TO FILE REHEARING

MOTION AND, IF FILED, DETERMINED

IN THE DISTRICT COURT OF APPEAL

OF FLORIDA

SECOND DISTRICT

WALTER SCOTT FUNDERBURK, )

DOC #583380, )

)

Appellant, )

)

v. ) Case No. 2D18-4125

)

STATE OF FLORIDA, )

)

Appellee. )

)

Opinion filed June 21, 2019.

Appeal pursuant to Fla. R. App. P. 

9.141(b)(2) from the Circuit Court for 

Manatee County; Charles Sniffen, Judge.

Walter Scott Funderburk, pro se.

PER CURIAM.

Affirmed. 

CASANUEVA, BLACK, and SALARIO, JJ., Concur.
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 01-6684

ISAAC EUGENE SLAPPY,

Plaintiff - Appellant,

and

JEFFERY RAY ADDY; MANSA MUSA BANSHEE,

Plaintiffs,

versus

J. BRYANT DIEHL; TOP REPUBLIC TOBACCO,

Defendants - Appellees.

No. 01-6795

JEFFERY RAY ADDY,

Plaintiff - Appellant,

and

ISAAC EUGENE SLAPPY; MANSA MUSA BANSHEE,

Plaintiffs,
2

versus

J. BRYANT DIEHL; TOP REPUBLIC TOBACCO,

Defendants - Appellees.

Appeals from the United States District Court for the District of

South Carolina, at Columbia. David C. Norton, District Judge.

(CA-99-3125-3-18BC)

Submitted: July 12, 2001 Decided: July 20, 2001

Before WILLIAMS, MICHAEL, and MOTZ, Circuit Judges.

Affirmed by unpublished per curiam opinion.

Isaac Eugene Slappy, Jeffery Ray Addy, Appellants Pro Se. Terry B.

Millar, TERRY B. MILLAR, L.L.C., Rock Hill, South Carolina; Thomas

Frank Dougall, BOWERS, ORR & DOUGALL, Columbia, South Carolina, for

Appellees.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
3

PER CURIAM:

Isaac Eugene Slappy and Jeffery Ray Addy appeal the district

court’s orders denying relief on their motions for relief from

judgment. We have reviewed the records and the district court’s

opinions and find no reversible error. Accordingly, we affirm on

the reasoning of the district court. Addy v. Diehl, No. CA-99-

3125-3-18BC (D.S.C. filed Mar. 22, 2001; entered Mar. 23, 2001;

filed and entered Mar. 26, 2001). We deny Addy’s motion for

appointment of counsel on appeal. We dispense with oral argument

because the facts and legal contentions are adequately presented in

the materials before the court and argument would not aid the

decisional process.

AFFIRMED
I 

110TH CONGRESS 

2D SESSION H. R. 5194 

To extend the temporary suspension of duty on Clethodim. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 29, 2008 

Mrs. TAUSCHER introduced the following bill; which was referred to the 

Committee on Ways and Means 

A BILL 

To extend the temporary suspension of duty on Clethodim. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. CLETHODIM. 

4 (a) IN GENERAL.—Heading 9902.24.74 of the Har5 monized Tariff Schedule of the United States is amended 

6 by striking ‘‘12/31/2009’’ and inserting ‘‘12/31/2011’’. 

7 (b) EFFECTIVE DATE.—The amendment made by 

8 subsection (a) applies with respect to goods entered, or 

9 withdrawn from warehouse for consumption, on or after 

10 the 15th day after the date of the enactment of this Act. 

Æ 


wwoods2 on PRODPC68 with BILLS
I 

110TH CONGRESS 

2D SESSION H. R. 5363 

To suspend temporarily the duty on high current ground fault circuit 

interrupters. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 12, 2008 

Mr. ACKERMAN introduced the following bill; which was referred to the 

Committee on Ways and Means 

A BILL 

To suspend temporarily the duty on high current ground 

fault circuit interrupters. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. CERTAIN HIGH CURRENT GROUND FAULT CIR4 CUIT INTERRUPTERS. 

5 (a) IN GENERAL.—Subchapter II of chapter 99 of 

6 the Harmonized Tariff Schedule of the United States is 

7 amended by inserting in numerical sequence the following 

8 new heading: 

‘‘ 9902.85.35 High current ground fault 

circuit interrupters of 15 

amps or more (provided for 

in subheading 8536.30.80) ... Free No change No change On or before 

12/31/2011 ’’. 


pwalker on PROD1PC71 with BILLS
2 

•HR 5363 IH

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies to goods entered, or withdrawn from 

3 warehouse for consumption, on or after the 15th day after 

4 the date of the enactment of this Act. 

Æ 


pwalker on PROD1PC71 with BILLS
Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO TITLE 18,

UNITED STATES CODE, SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, D. Joseph Gersuk, Executive Vice President, Chief Financial Officer of ANGIODYNAMICS, Inc. (the Company), certify, pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to the best of my knowledge:



|1. | the quarterly report on Form 10-Q of the Company for the fiscal quarter ended February 28, 2010 (the Report) fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
|-- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|2. | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|-- | ----------------------------------------------------------------------------------------------------------------------------------------------------

Date: April 9, 2010



|                                                                   
|-------------------------------------------------------------------
|/s/ D. Joseph Gersuk                                               
|D. Joseph Gersuk, Executive Vice President, Chief Financial Officer
```

[Congressional Bills 110th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5121 Introduced in House (IH)]

110th CONGRESS
  2d Session
                                H. R. 5121

     To extend the temporary reduction of duty on cyclopropane-1,1-
                   dicarboxylic acid, dimethyl ester.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            January 23, 2008

 Mr. Hulshof introduced the following bill; which was referred to the 
                      Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
     To extend the temporary reduction of duty on cyclopropane-1,1-
                   dicarboxylic acid, dimethyl ester.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. CYCLOPROPANE-1,1-DICARBOXYLIC ACID, DIMETHYL ESTER.

    (a) In General.--Heading 9902.10.69 of the Harmonized Tariff 
Schedule of the United States (relating to cyclopropane-1,1-
dicarboxylic acid, dimethyl ester) is amended by striking the date in 
the effective period column and inserting ``12/31/2011''.
    (b) Effective Date.--The amendment made by subsection (a) applies 
to goods entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
Exhibit 32.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                       AS ADOPTED PURSUANT TO SECTION 906
                        OF THE SARBANES-OXLEY ACT OF 2002

      In connection with the Quarterly Report of Chardan China Acquisition Corp.
(the "Company") on Form 10-QSB for the period ending March 31, 2005 (the
"Report"), as filed with the Securities and Exchange Commission on the date
hereof, I Li Zhang, Chief Financial Officer of the Company, certify pursuant to
18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act
of 2002, that:

      1. The Report fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934, as amended; and

      2. The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.

By: /s/ Li Zhang                                             Dated: May 16, 2005
    -------------------------------------
    Li Zhang
    Chief Financial Officer
    (Principal Financial and Accounting Officer)
<Page>

                                                               Exhibit 10.23


                            [LEADERS BANK LETTERHEAD]


July 28, 2005


Michael T. Flavin, Ph.D.
Chief Executive Officer
Advanced Life Sciences, Inc.
1440 Davey Road
Woodridge, IL 60517

Dear Dr. Flavin:

This Letter of Commitment shall serve to restructure the term of repayment of
all of the debt outstanding as of the date of this Letter of Commitment
provided by the Leaders Bank to Advanced Life Sciences, Inc. (the "Debt").

The effectiveness of this Letter of Commitment shall be contingent upon the
closing of the Initial Public Offering of Advanced Life Sciences Holdings,
Inc. (the "IPO"). Upon the effectiveness of this Letter of Commitment, both
parties agree to take any and all action required to amend and/or restate the
loan documents in place between the parties to incorporate the terms agreed
to hereunder.

     -  TERM- The Debt is hereby restructured to have principal become due and
        payable in one lump sum on December 21, 2007. In addition, the
        Leaders Bank hereby agrees to waive all rights to call this Debt upon
        demand except in the event of default as described in the loan
        documents;

     -  NET PROCEEDS- The Company hereby agrees to deposit 65% of the net
        proceeds raised in the IPO with the Leaders Bank within five (5)
        days of the closing of the IPO; and

     -  ALL OTHER TERMS (collateral, interest rate, guarantors, covenants,
        subordination, etc.)- all other terms shall remain substantially the
        same as the terms agreed to in those certain loan documents executed
        by the parties.

If this Letter of Commitment is acceptable to you, please indicate your
approval by signing in the space provided below.


Sincerely,


/s/ JAMES E. LYNCH
James E. Lynch
President
The Leaders Bank


/s/ Michael T. Flavin
--------------------------------
Michael T. Flavin
Chairman and CEO
Advanced Life Sciences, Inc.
```

[Congressional Bills 110th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5272 Introduced in House (IH)]

110th CONGRESS
  2d Session
                                H. R. 5272

          To reduce temporarily the duty on Corvus herbicide.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            February 7, 2008

 Mrs. Capito introduced the following bill; which was referred to the 
                      Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
          To reduce temporarily the duty on Corvus herbicide.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. CORVUS HERBICIDE.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``      9902.01.00       Product mixtures    1.9%         No change        No change        On or before 12/ ''.
                          containing                                                         31/2011.......
                          Thiencarbazone-
                          methyl (Methyl 4-
                          ({[(3-methoxy-4-
                          methyl-5-oxo-4,5-
                          dihydro-1H-1,2,4-
                          triazol-1-
                          yl)carbonyl]amino
                          }sulfonyl)-5-
                          methylthiophene-3-
                          carboxylate) &
                          Isoxaflutole(5-
                          Cyclospropyl-4-(2-
                          Methylsulfonyl-4-
                          Trifluoromethylbe
                          nxoyl)Isoxazole)
                          &
                          Cyprosulfamide(N-
                          ({4-
                          [(Cyclopropylamin
                          o)carbonyl]phenyl
                          }sulfonyl)-2-
                          methoxybenzamide)
                          (CAS Nos. 317815-
                          83-1, 141112-29-
                          0, 221667-31-8)
                          (provided for in
                          subheading
                          3808.93.15)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
to articles entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```